Recent Updates
Recently added Catalysts

AUR103 Calcium

Phase 2

Neuroendocrine (NE) Tumors | Small molecule | Oncology |Dr. Reddy's Laboratories Ltd|Last Updated: Jun 11, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDDMC
Total Trials1
Total Enrollment30

FDA Designations

No designations recorded

Clinical trial landscape

AUR103 Calcium · 1 trial · 2 indications

Phase 2 1
NCT07640737AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study)Neuroendocrine (NE) Tumors
NOT YET_RECRUITING30 Analytics
PHASE2NOT YET_RECRUITING
AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study)
Neuroendocrine (NE) Tumors
NCT0764073730
Unlock trial analytics

Study Endpoints

Primary Endpoints

Objective response rate
3rd week (Days 15-21) of Cycle 2, and thereafter every 2 cycles up till Cycle 6 (i.e., between Day 15-21 of Cycles 4, 6) and then every 3 cycles (i.e., towards the end of Cycle 9, 12). Each treatment cycle will be 28 days in length.

Objective response rate (\[ORR\] = CR + PR) by RECISTv1.1.

Secondary Endpoints

Efficacy: Time to response (TTR)
3rd week (Days 15-21) of Cycle 2, and thereafter every 2 cycles up till Cycle 6 (i.e., between Day 15-21 of Cycles 4, 6) and then every 3 cycles (i.e., towards the end of Cycle 9, 12). Each treatment cycle will be 28 days in length.
Efficacy: Duration of Response (DOR)
3rd week (Days 15-21) of Cycle 2, and thereafter every 2 cycles up till Cycle 6 (i.e., between Day 15-21 of Cycles 4, 6) and then every 3 cycles (i.e., towards the end of Cycle 9, 12). Each treatment cycle will be 28 days in length.
Efficacy: Stable Disease (SD)
3rd week (Days 15-21) of Cycle 2, and thereafter every 2 cycles up till Cycle 6 (i.e., between Day 15-21 of Cycles 4, 6) and then every 3 cycles (i.e., towards the end of Cycle 9, 12). Each treatment cycle will be 28 days in length.
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Phase 2 single agent study AUR103 calcium administered as 200 mg or 300 mg twice daily.EXPERIMENTALAUR103 Calcium 200mg or 300mg will be administered twice daily

Interventions

NameTypeDescription
AUR103 CalciumDRUGAUR103 Calcium 200mg or 300mg administered twice daily
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 99 Years
SexALL
Healthy VolunteersNo
Study Sites5

Inclusion Criteria: 1. Age ≥ 18 years. 2. Eastern Coorperative Oncology Group (ECOG) Performance status of 0 or 1. 3. Pathologically confirmed, well or moderately differentiated (G1 or G2), advanced (unresectable or metastatic), neuroendocrine tumour. 4. Patients should have progressed after at lea...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about AUR103 Calcium

What is AUR103 Calcium used for?

AUR103 Calcium is an investigational small molecule being studied for the treatment of advanced neuroendocrine tumors, including neuroendocrine tumors of gastrointestinal origin. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.

Who is developing AUR103 Calcium?

AUR103 Calcium is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed on the stock exchange under the ticker symbol RDY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with advanced neuroendocrine tumors.

What phase is AUR103 Calcium in?

AUR103 Calcium is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being evaluated in clinical trials for the treatment of advanced neuroendocrine tumors.

What clinical trials is AUR103 Calcium in?

AUR103 Calcium is being studied in a Phase 2 clinical trial with the identifier NCT07640737, titled 'AUR103 Calcium in Advanced Neuroendocrine Tumours (BHARAT-3 Study)'. This trial is planned to enroll 30 participants in the United States and is not yet recruiting.

How does AUR103 Calcium work?

AUR103 Calcium is a small molecule therapeutic. Its specific molecular target has not been disclosed in the available information, so the exact mechanism of action is not publicly detailed.